InsiderTrades

Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.

Accepted 2025-01-13 00:00:00 ET · period of report 2025-01-08 · accession 0001601830-25-000010 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2025-01-13 2025-01-08+ RXRX Gibson Christopher CEO, Dir C - Cnv Deriv $0.00 +40.0K 756.6K +6% $0
DM 2025-01-13 2025-01-08+ RXRX Gibson Christopher CEO, Dir S - Sale $7.18 -40.0K 736.6K -5% -$287.2K
DM 2025-01-13 2025-01-08+ RXRX Gibson Christopher CEO, Dir C - Cnv Deriv $0.00 -40.0K 5.98M -0.7% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Common Stock 2025-01-08 C A 20,000 $0.00 756,633 D — —
2 Common Class A Common Stock 2025-01-10 S D 20,000 $7.05 736,633 D — —
3 Common Class A Common Stock 2025-01-10 C A 20,000 $0.00 756,633 D — —
4 Common Class A Common Stock 2025-01-08 S D 20,000 $7.31 736,633 D — —
5 Derivative Class B Common Stock 2025-01-08 C D 20,000 $0.00 5,996,700 D $0.00 · — to — 20,000 Class A Common Stock (F3) Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
6 Derivative Class B Common Stock 2025-01-10 C D 20,000 $0.00 5,976,700 D $0.00 · — to — 20,000 Class A Common Stock (F3) Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.